No Data
No Data
ProMIS Neurosciences Director Shafmaster Purchases $255,750 in Stock
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish From Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Express News | ProMIS Neurosciences Inc Files for Resale From Time to Time of 56.5 Mln Common Shares of Co by Selling Stockholders - SEC Filing
No Data